Comparative humoral response of mRNA and inactivated vaccines against COVID-19 in healthy adults aged 60 years and older
The Journal of Infection in Developing Countries · 2023
DOI: 10.3855/jidc.16842 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infection in Developing Countries, 2023. Verfasst von Meryem Güvenir und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cyprus Health and Social Sciences University, Faculty of Medicine, Department of Medical Microbiology, Güzelyurt, Cyprus. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
A vaccine against coronavirus disease 2019 (COVID-19) is critically needed for older adults because of the increased morbidity and mortality rates. Methodology: In this prospective study, we analysed the titre magnitude of the IgG antibodies directed against the SARS-CoV-2 Spike Protein S1 (S1-RBD) antigen in both CoronaVac and Pfizer-BioNTech groups. The samples were tested to detect antibodies that bind to the receptor-binding domain of the spike protein of SARS-CoV-2 using the Enzyme-Linked Immunosorbent Assay (ELISA) technique with SARS-CoV-2 IgG II Quant. The cut-off value was > 50 AU/mL. GraphPad Prism software was used. Statistical significance was defined at p < 0.05.
Results
The CoronaVac group (12 females, 13 males) had a mean age of 69.64 ± 1.38 years. The Pfizer-BioNTech group (13 males, 12 females) had a mean age of 72.36 ± 1.44 years. The anti- S1-RBD titre decrease rate from the 1st to the 3rd month for CoronaVac and Pfizer-BioNTech groups was 74.31% and 86.48%, respectively. There was no statistically significant difference in the antibody titre between the 1st month and 3rd month for the CoronaVac group. However, there was a significant difference between the 1st and 3rd month in the Pfizer-BioNTech group. In addition, there was no statistically significant difference in the genders between the 1st and 3rd month of the antibody titres for both the CoronaVac Pfizer-BioNTech group.
Conclusions
The levels of anti-S1-RBD, the preliminary outcome data of our study, represents one piece of the puzzle of humoral response and duration of vaccination protection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cyprus Health and Social Sciences University, Faculty of Medicine, Department of Medical Microbiology, Güzelyurt, Cyprus.
- Cyprus Health and Social Sciences University, Faculty of Medicine, Department of Immunology, Güzelyurt, Cyprus.
- Near East University, Faculty of Medicine, Department of Biochemistry, Nicosia, Cyprus.
- Near East University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Nicosia, Cyprus.
- İnönü University, Faculty of Medicine, Department of Medical Microbiology, Malatya, Turkey.
Zitieren
APA
Güvenir, M., Yürüker, Ö., Yetkin, O., Süer, K., & Otlu, B. (2023). Comparative humoral response of mRNA and inactivated vaccines against COVID-19 in healthy adults aged 60 years and older. The Journal of Infection in Developing Countries. https://doi.org/10.3855/jidc.16842
Vancouver
Güvenir M, Yürüker Ö, Yetkin O, Süer K, Otlu B. Comparative humoral response of mRNA and inactivated vaccines against COVID-19 in healthy adults aged 60 years and older. The Journal of Infection in Developing Countries. 2023. doi:10.3855/jidc.16842
BibTeX
@article{Gvenir2023,
author = {Güvenir, Meryem and Yürüker, Özel and Yetkin, Osman and Süer, Kaya and Otlu, Barış},
title = {Comparative humoral response of mRNA and inactivated vaccines against COVID-19 in healthy adults aged 60 years and older},
journal = {The Journal of Infection in Developing Countries},
year = {2023},
doi = {10.3855/jidc.16842}
}
EUVIMED